---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-105560"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2022-10-04T23:59:59+00:00"
generated_at: "2026-06-23T05:36:05.413342+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pfizer exercises option on Voyager TRACER capsid for rare CNS disease; $10M fee

## Summary
- Pfizer exercised License Option for Voyager's novel capsid for an undisclosed rare neurologic CNS disease gene therapy program.
- Voyager receives $10M upfront fee and is eligible for future development, regulatory and sales milestone payments plus royalties.
- Pfizer did not exercise option for cardiovascular target; rights for that target revert to Voyager.
- Option follows prior agreement from Oct 2021 under which Pfizer evaluated Capsids through Sept 30, 2022.

## SEC filing metadata
- accession: 0001104659-22-105560
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2022-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465922105560/0001104659-22-105560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465922105560/tm2227299d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-105560
- JSON: https://secwatch.observer/filing/0001104659-22-105560.json
- Plain text: https://secwatch.observer/filing/0001104659-22-105560.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.